Biotech & Pharma

Fortress to sell priority review voucher for $205M

24 sec read6 views0 listens

Fortress Biotech and Cyprium sold a priority review voucher for $205 million, marking one of the highest prices for such a voucher recently. This highlights the significant financial value drug developers place on speeding up FDA approval processes. Content creators should note the example of leveraging unique assets for substantial monetary gains in specialized markets.

Read the full article at Endpoints News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Cybersecurity9 hours ago29 sec read

Waiting for care: Why Canadians' healthcare expectations are colliding with reality

A new survey reveals that nearly half of Canadians waited longer than a week for their most recent routine medical appointment, despite expecting quicker access. This growing gap between expectations and reality highlights significant challenges in t...

Ali Nemati

Legal & Policy9 hours ago25 sec read

Animal Justice Calls on Fisheries Minister to Investigate Beluga's Death, Demands Pause on Marineland Transports

Animal Justice is urging the federal Fisheries Minister to investigate the death of a beluga whale named Peekachu who died shortly after being transported from Marineland to Shedd Aquarium. The organization demands a halt to further transports until ...

Ali Nemati

Real Estate & Home10 hours ago25 sec read

'Spend one night here': Anger explodes over new Western Sydney airport night flights

Residents near the new 24/7 Western Sydney International Airport are facing severe sleep disruptions due to frequent nighttime cargo flights, leading to health issues and potential relocation. This development highlights the need for effective noise ...

Ali Nemati